17005-Urothelial Cancer-NA-421

Urothelial Cancer

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Address

433 SW 10th Street
Ocala, FL 34471
P: (352) 732-4032

Find a Clinical Trial

Use the abbreviation for your state (ie. FL, TX, NV)
Search by practice name, trial titles, indicators and specific disease types.